Table 2 Cost-effectiveness analysis for M72/AS01E and BCG-revaccination Policy Scenarios
Scenario | Total costs (USD, 1000Â s) | Total DALYs (1000Â s) | Total DALYs averted (1000Â s) | Incremental cost (USD, 1000Â s) | Incremental DALYs averted (1000Â s) | Cost (USD) per DALY averted |
|---|---|---|---|---|---|---|
M72/AS01E policy scenarios | ||||||
 No-new-vaccine | 14,262,475 | 3,991,720 | – | 14,262,475 | – | – |
 Elderly ages (routine age 60, campaign for ages 61 +) | 17,523,764 | 3,986,463 | 5257 | – | – | Weakly dominated |
 Basecase (routine age 15, campaign for ages 16–34) | 19,596,068 | 3,954,863 | 36,857 | 5,333,593 | 36,857 | $145 |
 Older ages (campaign for ages 18–55) | 21,456,380 | 3,953,202 | 38,518 | 1,860,312 | 1661 | $1120 |
BCG-revaccination policy scenarios | ||||||
 No-new-vaccine | 14,262,475 | 3,991,720 | – | 14,262,475 | – | – |
 Basecase (routine age 10, campaign for ages 11–18) | 14,918,037 | 3,962,629 | 29,091 | 655,526 | 29,091 | $23 |
 Older ages (routine age 15, campaign for ages 16–34) | 15,819,567 | 3,961,671 | 30,049 | 901,530 | 958 | $941 |
 Elderly ages (routine age 60, campaign for ages 61 +) | 15,922,705 | 3,991,270 | 450 | – | – | Strongly dominated |